Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Is Climbing Higher Today

By Keith Speights - Jun 24, 2021 at 12:13PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are breathing easier after the FDA's response to a potential link between Moderna's vaccine and heart inflammation issues.

What happened

Shares of Moderna (MRNA -2.74%) were climbing 3.7% higher as of 11:45 a.m. EDT on Thursday. The gain appears to reflect a sigh of relief among investors after the U.S. Food and Drug Administration (FDA) stated that it would add a warning to the label of Moderna's COVID-19 vaccine about the potential for adolescents and young adults to experience rare heart inflammation issues. This FDA warning isn't likely to impact Moderna financially.

So what

A Centers for Disease Control and Prevention (CDC) advisory committee met on Wednesday to review data related to a potential link between messenger RNA vaccines and heart inflammation cases. Investors seemed to fret somewhat about how potential actions taken by the CDC and FDA in response might affect Moderna, with the biotech stock falling more than 4%.

Doctor giving a shot to a person with a healthcare professional watching.

Image source: Getty Images.

However, any such worries were overblown. There's no reason to expect that the new label warning will change the prospects for Moderna to win additional supply deals for its vaccine.

Now what

The main thing to watch with Moderna now is how the emergence of new coronavirus variants could impact the COVID-19 vaccine market. It's quite possible that the spread of the more contagious Delta variant could work in the company's favor as governments see an increased possibility of administering booster doses in the near future.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$153.67 (-2.74%) $-4.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
395%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.